CClinicalTrials.gg
CompletedNCT03286985preTIMEUpdated Oct 19, 2020

The Prevalence and Incidence of DVT in General ICU

An observational study in Deep Venous Thrombosis, sponsored by Masaryk Hospital Krajská zdravotní a.s.. Completed at 1 site in Czechia. Per ClinicalTrials.gov, last updated 2020-10-19.

Sponsored by Masaryk Hospital Krajská zdravotní a.s. · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Sex
All
01

Study summary

Deep venous thrombosis (DVT) represents a major problem in intensive care unit (ICU) patients. Despite the use of recommended pharmacological prophylaxis with low molecular weight heparin (LMWH), the incidence of DVT during ICU stay has been reported between 5 and 15 %. The incidence may vary due to many factors, for example the type of ICU population, the type of protocol of pharmacological prophylaxis and also the type of diagnostic approach. Before formerly planned clinical study targeted to lower DVT incidence by individualizing the dose of LMWH, the investigators decided to evaluate the real DVT incidence in the investigated ICU. The prevalence and incidence will be assessed by ultrasound testing in general ICU patients. on the sample of 200 patients. The investigators hypothesize DVT incidence of 5 %. The compliance to the local DVT prophylaxis protocol will be also evaluated.

Read the detailed description

Type of the study: Observational prospective cohort study. Hypothesis: Despite appropriate prophylaxis of deep venous thrombosis in general ICU patients in accordance with the current guidelines, the incidence of deep venous thrombosis is 5 - 10%.

Sample size: 200 consecutive general ICU patients. Inclusion and exclusion criteria: defined in the Eligibility section. Protocol description: All patients admitted to ICU with expected period of the stay longer than 72 hours will be evaluated for the presence of deep venous thrombosis by ultrasound testing during the first 48 hours of ICU stay. Thereafter, each participant will be examined by ultrasound testing twice a week until the discharge from ICU. All patients will receive deep venous thrombosis prophylaxis following the current guidelines. All patients with positive finding of deep venous thrombosis will be managed in accordance with the current guidelines.

Ultrasound examination for deep venous thrombosis: Ultrasound compression test at the following locations: common femoral vein at the groin, deep femoral vein, popliteal vein, both extremities.

02

Conditions studied

  • Deep Venous Thrombosis
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

General ICU patients

All general ICU patients meeting exclusion and inclusion criteria.

Inclusion criteria

Inclusion criteria:

  1. General ICU patient with expected length of stay more than 72 hours

Exclusion criteria

Exclusion Criteria:

  1. Inability to perform ultrasound investigation for deep venous thrombosis (for medical or technical reasons)
  2. ICU stay shorter than 72 hours
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (actual)
Patient registry
No

Groups and cohorts

  • General ICU patients

    No intervention is associated with inclusion to the study (observational study). Included will be all patients admitted to general ICU with ICU stay \>72 hours, having deep venous thrombosis prophylaxis appropriate to clinical setting and following the recent guidelines. All study participants will undergo repeated noninvasive ultrasound testing for deep venous thrombosis, which is normal part of the routine care in our ICU.

05

What researchers measure

Primary outcomes

  1. Incidence of deep venous thrombosis

    Number of patients with new onset deep venous thrombosis diagnosed during ICU stay (ie deep venoous thrombosis developed after the first 24 hours of ICU stay)

    Time frame: 24 hours from ICU admission to ICU discharge (up to 12 month)

Secondary outcomes

  1. Prevalence of deep venous thrombosis

    A number of patients with deep venous thrombosis diagnosed anytime during ICU stay (on admission and during ICU stay)

    Time frame: From ICU admission to ICU discharge (up to 12 month)

06

Study locations

1 site
  • Masaryk Hospital
    Ústí nad Labem, Česká Republika 40011, Czechia
07

References and documents

Publications

  • Qaseem A, Chou R, Humphrey LL, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2011 Nov 1;155(9):625-32. doi: 10.7326/0003-4819-155-9-201111010-00011. PubMed 22041951 ↗
  • Benes J, Skulec R, Jobanek J, Cerny V. Fixed-dose enoxaparin provides efficient DVT prophylaxis in mixed ICU patients despite low anti-Xa levels: A prospective observational cohort study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2022 May;166(2):204-210. doi: 10.5507/bp.2021.031. Epub 2021 May 27. PubMed 34042098 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03286985
Lead sponsor
Masaryk Hospital Krajská zdravotní a.s.
Responsible party
Jan Benes (MUDr. Ing., Masaryk Hospital Krajská zdravotní a.s.) — Principal investigator
First posted
Sep 19, 2017
Start date
Sep 1, 2017
Primary completion
Dec 31, 2017
Completion
Dec 31, 2017
Last update
Oct 19, 2020

Study contacts

Jan Beneš, MD
principal investigator · Department of Anesthesiology, Perioperative Medicine and Intensive Care, J.E. Purkinje University, Masaryk Hospital in Usti nad Labem, Usti nad Labem, Czech Republic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion